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Purpose: To assess the cognitive and sexual/hormonal functioning of prostate cancer patients treated with a
luteinizing hormone-releasing hormone (LH-RH) agonist, and the relationships thereof with adrenal and residual
testicular androgen levels.
Materials and methods: Previously, we reported the effect of a luteinizing hormone-releasing hormone (LH-RH)
agonist on testicular and adrenal androgen production in patients with prostate cancer. A 6-month treatment with
an LH-RH agonist significantly reduced testicular androgens by 90–95% and adrenal androgens by 26–40%. This
study evaluated the changes in cognitive and sexual/hormonal functions in the same cohort using the Mini-Mental
State Evaluation (MMSE) and Expanded Prostate Cancer Index Composite (EPIC) questionnaire, respectively. In
addition, the associations of each function with the serum testosterone (T), dihydrotestosterone (DHT), estradiol (E2),
dehydroepiandrosterone-sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione (A-dione), and cortisol
levels were studied.
Results: Cognitive functions did not change significantly during the treatment. Sexual functions were relatively low
before treatment and worsened significantly after 6 and 12 months of treatment. Interestingly, sexual bothers were
improved with the treatment. The treatment significantly worsened hormonal functions and bothers. Regarding
specific items in the hormonal domains, hot flashes and body weight changes were the main effects of worsened
hormonal function. Low levels of T and E2 and high levels of A-dione were associated with low MMSE scores at
6 months. Regarding sexual and hormonal functions, A-dione, E2, T, cortisol, and DHEA-S were associated with
poorer functioning and bother. Especially, low T levels and high E2 levels were the most significant factors associ-
ated with worse sexual and hormonal bothers.
Conclusion: The LH-RH agonist monotherapy worsened sexual and hormonal functions and hormonal bothers, but
not sexual bothers or cognitive functions. The changes in these functions were related to the testicular and adrenal
androgens levels.
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Table 1 Clinical characteristics of the enrolled patients
n 45
Age (±SD) 67.5 ± 3.5











Risk group Intermediate 16
High 29
PSA: prostate specific antigen.
G.S. Gleason score.
T:T category of TNM Classification of Malignant Tumours 7th Edition.
Risk group: D’Amico risk stratification.
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Prostate cancer is an androgen-dependent cancer. Long-
term androgen-deprivation therapy (ADT) is the standard
therapy for metastatic prostate cancer and is administered
in localized or locally progressive disease concomitant
with radiation therapy for the short or long term [1]. ADT
has several adverse effects [2,3]. ADT with luteinizing
hormone-releasing hormone (LH-RH) analogues is used
frequently for medical castration. Previously, we reported
the effect of an LH-RH agonist on reducing serum adrenal
androgen levels 6 and 12 months after initiating treatment
[4]. We also identified immunoreactive LH receptors in
the reticular layer of the adrenal glands and speculated
that the LH-RH agonist therapy reduced adrenal androgen
synthesis via reduced LH levels [4].
This study assessed the adverse effects of ADT in the
same cohort, focusing on cognitive and sexual/hormone
functions. We evaluated the changes in the health-
related quality of life (QOL) and cognitive functions
using the Expanded Prostate Cancer Index Composite
(EPIC) questionnaire [5,6] and Mini-Mental State Evalu-
ation (MMSE) [7]. In addition, the changes in the QOL
and cognitive function parameters were compared with
serum levels of testicular and adrenal androgens.
Materials and methods
Patients
Previously, we evaluated the serum testicular and ad-
renal androgen levels in 47 patients with prostate cancer
treated via 6-month neoadjuvant ADT with radiation
therapy, followed by adjuvant ADT (this treatment strat-
egy was reported previously by our study group [8]).
ADT was given as monotherapy; we prescribed the LH-
RH agonist leuprolide. Forty-five of the forty-seven pa-
tients had full QOL and cognitive function test data and
were included in this study. Table 1 shows the clinical
characteristics of the patients analyzed. Their ages ranged
from 61 to 75 years, with a mean age of 67.5 years. The
mean pretreatment prostate-specific antigen (PSA) level
was 13.0 ng/mL. Using the D’Amico risk stratification, 16
patients (35.6%) were categorized in the intermediate-risk
group and 29 patients (64.4%) in the high-risk group. This
study was approved by the Ethics Committee of the
Gunma University Faculty of Medicine, and written con-
sent was obtained from the enrolled patients.
QOL questionnaires and cognitive function test
The QOL was assessed using the EPIC questionnaire [5]
before and 6 and 12 months after initiating the LH-RH
agonist treatment. In this study, the sexual and hormo-
nal domains were analyzed. For the sexual domain, the
mean summary scores and subscale scores; i.e., sexual
function and bother, were assessed. For the hormonal
domain, the score changes for all items in the hormonaldomain were studied, as well as the mean summary and
subscale scores. Statistical significance was determined
using the χ2 test. Cognitive function was assessed using
Mini-Metal State Examination [7] and the same time
points as the QOL assessment. The examination was ad-
ministered by one medical technologist (R.S.).
Blood samples and measuring hormone levels
As described elsewhere [4], serum testosterone (T), di-
hydrotestosterone (DHT), estradiol (E2), dehydroepian-
drosterone (DHEA), and androstenedione (A-dione) were
measured using liquid chromatography-mass spectrometry
(LC-MS). DHEA-sulfate (DHEA-S) was measured using a
chemiluminescence enzyme immunity assay. In this study,
we also measured the serum cortisol levels using LC-MS.
Blood samples were taken before and 6 and 12 months
after initiating the LH-RH treatment. The changes in
hormone levels at each evaluation point are shown in
Table 2. As mentioned earlier, the serum levels of T, DHT,
E2, DHEA-S, DHEA, and A-dione decreased significantly
during the treatment, while the cortisol levels did not
differ significantly.
Evaluation of sexual, hormonal, and cognitive functions
according to age-adjusted hormone levels
To evaluate the association between the hormonal environ-
ments and QOL and MMSE scores at each observation
point, a multivariate analysis was performed. As dependent
variables, the MMSE scores, and sexual and hormonal sub-
scale scores were adopted (0 ≥mean, 1 <mean). Differential
values were the hormone levels and age at each observation
Table 2 Changes in the serum hormone levels in prostate cancer patients treated with a luteinizing hormone-releasing
hormone agonist
PRE 6MO 12MO Statistics
T Mean (ng/dL) 378.8 ± 145.1 9.6 ± 5.0 7.7 ± 4.6 P < 0.01 PRE vs, 12MO
Percentile change -97.5% -98.0%
DHT Mean (pg/mL) 420.2 ± 200.2 21.6 ± 12.2 20.8 ± 11.2 P < 0.01 PRE vs 6MO, 12MO
Percentile change -94.9% -95.0%
E2 Mean (pg/mL) 16.2 ± 5.2 1.3 ± 1.0 1.4 ± 1.0 p < 0.01 PRE vs 6MO, 12MO
Percentile change -92.2% -91.3%
DHEA-S Mean (μg/dL) 144.9 ± 66.6 107.2 ± 48.6 103.5 ± 54.3 P < 0.01 PRE vs 6MO, 12MO
Percentile change -26.1% -28.6%
DHEA Mean (ng/mL) 1.85 ± 0.91 1.38 ± 0.67 1.29 ± 0.65 P < 0.01 PRE vs 6MO, 12MO
Percentile change -25.1% -30.0%
A-dione Mean (pg/mL) 384.0 ± 133.5 231.7 ± 109.4 227.8 ± 119.7 p < 0.01 PRE vs 6MO, 12MO
Percentile change -39.7% -40.7%
cortisol Mean (ng/mL) 89.9 ± 26.7 94.9 ± 27.4 81.4 ± 23.4 Not significant
Percentile change 5.4% -10.4%
PRE: pretreatment 6MO: 6 months after initiation of LH-RH agonist treatment.
12MO: 12 months after initiation of LH-RH agonist treatment.
T: testosterone, DHT: dihydrotestosterone, E2; estradiol, DHEA-S: dehydroepiandrosterone-sulfate.
DHEA: dehydroepiandrosterone.
Percentile change: changes in comparison with pretreatment levels.
The percentile change is in comparison with the pretreatment levels. Values are expressed as means ± SD (standard deviation).
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nificant predictive factors were estimated. The statistical
analysis was performed using SPSS ver. 19.0 (SPSS,
Chicago, IL, USA).
Results
The changes in the MMSE scores are shown in Figure 1.
The mean pretreatment score was 28.7, and no signifi-
cant difference was observed after 6 or 12 months of
treatment. Stratification of the patients based on pre-
treatment scores; i.e., ≥mean or < mean, showed no sig-
nificant difference in the mean scores during treatmentFigure 1 Changes in MMSE scores. Values are expressed as
means ± SD. PRE: pretreatment, 6Mo: 6 months after initiation of
treatment, 12Mo: 12 months after initiation of treatment.in either the high or low baseline score groups (data not
shown).
Figure 2 shows the changes in the sexual and hormo-
nal scores. The summary scores of both the sexual and
hormonal domains worsened significantly during treat-
ment. Regarding the subscale scores, the sexual func-
tion scores worsened significantly, whereas the sexual
bother scores improved significantly. By contrast, the
scores for both hormonal function and bother wors-
ened significantly.
Tables 3 and 4 summarize the frequency of each item
for hormonal function and bother, respectively. The func-
tional and bother changes; i.e., hot flashes, were worsened
significantly during treatment. Significant body weight
gains were observed.
Finally, we studied the associations of cognitive func-
tion, sexual, and age-adjusted hormonal functions with
serum hormone levels. Low MMSE scores were associ-
ated with low E2 and cortisol and high A-dione levels at
6 months. None of the pretreatment hormone levels or
decreased hormone levels were significantly related to
the scores during the treatment. Regarding the sexual
and hormonal function and bother scores, A-dione, E2,
T, cortisol, and DHEA-S were associated with poorer
functioning and bother at each observation point, as
shown in Table 5. Low T levels were the factors most
significantly associated with worsened sexual and hor-
monal bother at 6 months.
Figure 2 Mean sexual and hormone domain scores including summary score and subscale scores. Values are expressed as means ± SD,
and pretreatment values are compared with those at each post-treatment sampling point. A difference was considered to be significant if the
p-value was less than 0.05 (# p < 0.05, * p < 0.01). EPIC: Expanded Prostate Cancer Index Composite. PRE: pretreatment, 6Mo: 6 months after
initiation of treatment, 12Mo: 12 months after initiation of treatment Summary score: S; sexual summary score including sexual function and
sexual bother scores. H; hormone summary score including hormone function and hormone bother scores. Subscale scores: SF; sexual function,
SB; sexual bother, HF; hormonal function, HB; hormone bother.
Table 3 Distribution of EPIC hormone function domain items before and after 6 and 12 months of androgen-deprivation
therapy
More than once a day About once a day More than once a week About once a week Rarely or never
Hot flashes*
Pre 4.4% 4.4% 0.0% 6.7% 84.4%
6Mo 33.3% 13.3% 6.7% 0.0% 46.7%
12Mo 44.4% 8.9% 2.2% 4.4% 40.0%
Breast tenderness
Pre 2.2% 0.0% 0.0% 0.0% 97.8%
6Mo 0.0% 2.2% 0.0% 0.0% 97.8%
12Mo 0.0% 0.0% 2.2% 2.2% 95.6%
Feel depressed
Pre 0.0% 2.2% 2.2% 13.3% 82.2%
6Mo 0.0% 2.2% 4.4% 8.9% 84.4%
12Mo 0.0% 0.0% 4.4% 13.3% 82.2%
Lack of energy
Pre 0.0% 6.7% 6.7% 22.2% 64.4%
6Mo 0.0% 4.4% 11.1% 15.6% 68.9%
12Mo 2.2% 6.7% 15.6% 15.6% 60.0%
Gained 5 kg or more Gained less than 5 kg No change Lost less than 5 kg Lost 5 kg or more
Change in body weight*
Pre 0.0% 2.2% 93.3% 4.4% 0.0%
6Mo 2.2% 31.1% 60.0% 6.7% 0.0%
12Mo 2.2% 35.6% 57.8% 4.4% 0.0%
*p < 0.001.
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Table 4 Distribution of the EPIC hormone bother domain items before and after 6 and 12 months of androgen-deprivation
therapy
No such symptom No problem Very small problem Small problem Moderate problem Big problem
Hot flashes*
Pre 80.0% 6.7% 11.1% 2.2% 0.0% 0.0%
6Mo 46.7% 11.1% 20.0% 8.9% 13.3% 0.0%
12Mo 31.1% 15.6% 17.8% 20.0% 8.9% 6.7%
Breast tenderness/enlargement
Pre 95.6% 2.2% 0.0% 0.0% 0.0% 2.2%
6Mo 93.3% 4.4% 2.2% 0.0% 0.0% 0.0%
12Mo 84.4% 8.9% 4.4% 2.2% 0.0% 0.0%
Loss of body hair
Pre 91.1% 6.7% 0.0% 0.0% 2.2% 0.0%
6Mo 86.7% 6.7% 6.7% 0.0% 0.0% 0.0%
12Mo 66.7% 15.6% 8.9% 6.7% 2.2% 0.0%
Feeling depressed
Pre 66.7% 8.9% 17.8% 4.4% 2.2% 0.0%
6Mo 62.2% 17.8% 8.9% 6.7% 4.4% 0.0%
12Mo 66.7% 17.8% 8.9% 6.7% 0.0% 0.0%
Lack of energy
Pre 57.8% 11.1% 15.6% 15.6% 0.0% 0.0%
6Mo 55.6% 17.8% 13.3% 8.9% 4.4% 0.0%
12Mo 46.7% 15.6% 28.9% 4.4% 2.2% 2.2%
Change in body weight
Pre 84.4% 11.1% 4.4% 0.0% 0.0% 0.0%
6Mo 57.8% 17.8% 15.6% 4.4% 2.2% 2.2%
12Mo 62.2% 20.0% 11.1% 4.4% 0.0% 2.2%
*p < 0.001.
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This study examined the changes in cognitive function
using the MMSE and in sexual and hormonal functions
using the EPIC questionnaire.
We observed no significant worsening in the MMSE
scores in this study. The effects of ADT on cognitive
functions are controversial. Nelson et al. [9] summarized
nine studies on this matter, and stated that ADT im-
paired cognitive functions subtly, especially the visuo-
spatial abilities and executive functioning. Alibhai et al.
[10] compared the cognitive functions of non-metastatic
prostate cancer patients treated with ADT with those of
prostate cancer patients not receiving ADT and healthy
controls. They observed no consistent evidence of ad-
verse effects on cognitive functions. In a similar study,
Mohile et al. [11] focused on the preexisting impairment
of cognitive functions in elderly subjects and stated that
the baseline prevalence of cognitive impairment affected
the results. We stratified the patients according to the
baseline MMSE scores and found no significant difference
during the study. Recently, Chao et al. [12] reported aprospective study of the effects of ADT on brain func-
tion using functional MRI. In that study, 6 months of
ADT clearly impaired brain activations during cognitive
control and functional brain connectivity on functional
MRI. Interestingly, cognitive function tests showed no
significant impairment at this point. Further studies of
the association of conventional cognitive function tests
with brain function imaging are warranted.
The QOL was assessed using the EPIC questionnaire,
which has been validated in Japanese [5]. The summary
scores of both sexual and hormonal functions at 6 and
12 months worsened significantly in comparison with
those before treatment. Although the sexual functions
worsened significantly while on ADT, sexual bother im-
proved during the treatment. This tendency was consist-
ent with the results of the validation study [5]. The
exact reason remains unknown; however, the loss of li-
bido might reduce the sexual desire that causes sexual
bother. The trends in the hormonal function and bother
scores were similar to and consistent with the validation
study [5].
Table 5 Association between hormone levels and the MMSE and EPIC scores: multivariate analysis
MMSE
6Mo hormone levels B Odds ratio 95% CI p
E2 -1.47 0.23 0.073-0.724 0.012
A-dione 0.021 1.02 1.006-1.036 0.006
cortisol -0.059 0.94 0.898-0.989 0.016
EPIC
Hormone levels and QOL at each observation point
PRE
Sexual bother A-dione -0.02 0.98 0.964-0.997 0.019
6Mo
Sexual bother E2 1.57 4.81 1.086-21.33 0.039
T -61.15 2.76 × 10-27 1.34 × 10-5-0.00057 0.026
DHT 0.21 1.017 1.028-1.484 0.024
Hormonal function E2 1.14 3.12 1.13-8.64 0.028
A-dione -0.019 0.98 0.97-0.998 0.026
Hormonal bother E2 2.006 7.44 1.82-30.30 0.005
T -30.8 4.19 × 10-14 4.32 × 10-24-0.00041 0.017
cortisol 0.076 1.08 1.02-1.14 0.008
12Mo
Sexual bother E2 1.082 2.95 1.11-7.82 0.030
Hormonal bother A-dione -0.0089 0.991 0.983-0.9997 0.042
DHEA-S -0.0174 0.983 0.966-0.999 0.049
B: regression coefficient.
PRE: pretreatment 6MO: 6 months after initiation of LH-RH agonist treatment.
12MO: 12 months after initiation of LH-RH agonist treatment.
T: testosterone, DHT: dihydrotestosterone, E2; estradiol, DHEA-S: dehydroepiandrosterone-sulfate.
A-dione: androstenedion, MMSE: mini-mental state examination.
EPIC: expanded postate cancer index composite.
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QOL assessments and showed the detailed changes in
the hormonal domain scores (Tables 3 and 4). Among
hormonal functions, hot flashes and body weight gain
were worsened significantly on ADT. Only hot flashes
were significantly associated with bother. Body weight
gain is one of the important adverse events caused by
ADT. In the present study, about one-third of all pa-
tients experienced body weight gain after 6 months of
ADT. Interestingly, the proportions of patients experien-
cing body weight gains >5 kg or ≤ 5 kg were very similar
at 6 and 12 months. Lee et al. [13] studied the effect of
ADT on body composition changes in prostate cancer
patients. On ADT, the fat and lean masses were in-
creased significantly only in patients not receiving ADT.
By contrast, a significant loss in bone mineral density
occurred in both the patients not receiving ADT or
those pretreated with ADT. Our findings regarding body
weight changes are consistent with these findings. This
information would be helpful when obtaining informed
consent from patients who need ADT. Gay et al.
reported on the QOL assessment using the EPICquestionnaire in patients with prostate cancer treated
with neoadjuvant ADT [14]. The sexual and hormonal
summary scores were decreased significantly after
2 months of neoadjuvant ADT. In this study, the ques-
tion items for hormone bother were summarized. The
percentage of patients with bother tended to be higher
in the cohort of Gay et al. [14] in comparison with our
study. This might be due to age differences, 70.2 vs.
67.5 years, ethnic differences, or tolerance of ADT.
Finally, we investigated the association of cognitive,
sexual, and hormone functions with serum hormone
levels. In a previous study, we detected a significant de-
crease in both testicular and adrenal androgens after
LH-RH agonist treatment [4]. The decreases in T and E2
were associated with cognitive functions [15]. However,
the association of adrenal androgen levels with cognitive
or sexual/hormone functions has not been examined.
Furthermore, cortisol levels and stress are related [16],
so we also examined the cortisol levels. In the cognitive
function test, low E2 levels were significantly related to
worse MMSE scores in our study. This finding was
consistent with Salminen et al. [17], who investigated
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prostate cancer. The serum E2 levels before and after 6
and 12 months of treatment were correlated with visual
memory and verbal fluency. In our study, the A-dione
and cortisol levels were associated with the MMSE
scores. The odds ratios of A-dione and cortisol were
1.02 and 0.94, respectively, and the role of hormonal
changes was unknown. Regarding sexual and hormone
functions, low T levels were the factor most significantly
associated with worse sexual and hormone bother. High
E2 levels were significantly associated with worse sexual
bother and both hormone function and bother. In males,
E2 is synthesized from T by aromatization in peripheral
tissues, including fat [18]. ADT causes a change in body
composition, and the fat mass generally increases [13].
In our series, 33.3% of the patients experienced signifi-
cant body weight gain during the first 6 months of ADT.
High E2 levels might affect the QOL changes via this
mechanism. High cortisol levels were associated with
worse hormonal bother. Cortisol is the most researched
stress hormone [16]. Stress during ADT might be associ-
ated with high cortisol levels. We observed that low
adrenal androgen A-dione and DHEA-S levels were sig-
nificantly associated with worse sexual and hormonal
functions. No relationship between adrenal androgen
levels and these functions has been reported. Recently,
a new class of CYP17 inhibitor, abiraterone acetate,
was approved for treating castration-resistant prostate
cancer [19]. Abiraterone acetate significantly reduced
the serum adrenal and testicular androgen levels [20].
Further analyses focusing on sexual and hormonal
functions are warranted in patients treated with new
hormone agents.
This study had several limitations. The first is the
small number of patients subjected to the multivariate
analysis. Another is the evaluation of cognitive function.
We used only MMSE scores, and this score does not
cover details of cognitive functions. However, this is the
first study to examine the association of testicular and
adrenal androgen levels and ADT with cognitive and
sexual/hormonal functions. Further large-scale studies
are warranted.Conclusion
LH-RH agonist monotherapy worsened sexual and hor-
monal functioning and hormonal bother, but not sexual
bother or cognitive function, as assessed by the MMSE
and EPIC questionnaires. The observed changes were as-
sociated with adrenal and residual testicular androgen
levels.
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